255 related articles for article (PubMed ID: 36527328)
1. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies.
Beland B; Hahn C; Jamani K; Chhibber S; White C; Atkins H; Storek J
Muscle Nerve; 2023 Feb; 67(2):154-157. PubMed ID: 36527328
[TBL] [Abstract][Full Text] [Related]
2. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.
Morren J; Li Y
Muscle Nerve; 2018 Sep; 58(3):344-358. PubMed ID: 29461627
[TBL] [Abstract][Full Text] [Related]
3. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.
Bryant A; Atkins H; Pringle CE; Allan D; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Hopkins H; Huebsch L; McDiarmid S; Sabloff M; Sheppard D; Tay J; Bredeson C
JAMA Neurol; 2016 Jun; 73(6):652-8. PubMed ID: 27043206
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report.
Sossa Melo CL; Peña AM; Salazar LA; Jiménez SI; Gómez ED; Chalela CM; Ayala-Castillo M; Peña IM
Neuromuscul Disord; 2019 Feb; 29(2):142-145. PubMed ID: 30639064
[TBL] [Abstract][Full Text] [Related]
5. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
6. Remission of severe myasthenia gravis after autologous stem cell transplantation.
Schlatter MI; Yandamuri SS; O'Connor KC; Nowak RJ; Pham MC; Obaid AH; Redman C; Provost M; McSweeney PA; Pearlman ML; Tees MT; Bowen JD; Nash RA; Georges GE
Ann Clin Transl Neurol; 2023 Nov; 10(11):2105-2113. PubMed ID: 37726935
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
8. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
9. MuSK Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paresis: A Case Report and Literature Review.
Santilli A; Stitt D
Neurologist; 2021 Sep; 26(5):175-177. PubMed ID: 34491934
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and outcomes of myasthenia gravis patients with double positive antibodies against acetylcholine receptor and muscle-specific tyrosine kinase].
Lu YR; Yu L; Ma Q; Chen P; Qiu L; Ou CY; Lin ZZ; Liu WB
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):942-947. PubMed ID: 35385966
[No Abstract] [Full Text] [Related]
11. Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.
Martinez-Harms R; Barnett C; Alcantara M; Bril V
Eur J Neurol; 2024 Jan; 31(1):e16022. PubMed ID: 37531447
[TBL] [Abstract][Full Text] [Related]
12. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
Caress JB; Hunt CH; Batish SD
Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.
Huang Q; Li F; Zhao S
BMC Neurol; 2022 Mar; 22(1):73. PubMed ID: 35246057
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
15. Dysautonomia as the Presenting Symptom in Anti-Muscle-Specific Kinase Antibody Myasthenia Gravis.
Bekooij TJS; Gilhuis HJ; Dawson L; Niks EH
J Neuromuscul Dis; 2020; 7(1):47-50. PubMed ID: 31868676
[TBL] [Abstract][Full Text] [Related]
16. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
17. Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
Bokoliya SC; Kumar VP; Nashi S; Polavarapu K; Nalini A; Patil SA
Clin Chim Acta; 2018 Nov; 486():34-35. PubMed ID: 30006288
[TBL] [Abstract][Full Text] [Related]
18. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
[TBL] [Abstract][Full Text] [Related]
19. [Myasthenia gravis: current status of antibody diagnostics and aspects on refractory myasthenia gravis].
Wenninger S; Schoser B
Fortschr Neurol Psychiatr; 2018 Sep; 86(9):551-558. PubMed ID: 30248688
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia gravis patients with anti-MuSK antibodies.
Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
